The researchers explored the role of resilience in mediating the association between stigma and psychosocial adjustment.
Advertisement
Dr. Liu explains how these two studies are shaping standards of care and the treatment landscape in SCLC.
The systematic review examined interventions for improving patient function at any stage or phase of lung cancer.
The phase 3 study compared the efficacy data of benmelstobart plus anlotinib with that of pembrolizumab monotherapy.
Dr. Culver discusses the organization's work at ASCO and the importance of having a patient advocacy presence at the meeting.
The results of the interim analysis comparing safety and efficacy were presented at the 2025 ASCO Annual Meeting.
Malignant peritoneal mesothelioma is a rare disease with unspecific abdominal symptoms, often diagnosed at an advanced stage.
Xiuning Le, MD, PhD, discusses the phase 3 trial, which follows the SOHO-01 trial of the oral TKI.
Researchers compared sacituzumab tirumotecan, a TROP2-directed antibody drug conjugate, with platinum-based chemotherapy.
The approval is for adults who have experienced disease progression on or after platinum-based chemotherapy.
Other analyses suggest that lack of ctDNA clearance with neoadjuvant therapy or with MRD postsurgery leads to worse outcomes.
Advertisement
Editorial Board
Mara B. Antonoff, MDEditor | Associate Professor, the University of Texas MD Anderson Cancer Center
Stephen V. Liu, MDEditor | Associate Professor, Georgetown University
Coral Olazagasti, MDEditor | Assistant Professor, Sylvester Comprehensive Cancer Center, University of Miami
Eric Singhi, MDEditor | Assistant Professor, the University of Texas MD Anderson Cancer Center
Advertisement
Roundtable Discussions
Expert Interviews
Conference Coverage
Find key news and updates from the European Lung Cancer Congress 2025.
Find lung cancer news and updates from AACR 2025.
Find key news in thoracic oncology from the 61st Annual Meeting of the Society of Thoracic Surgeons.
Find the latest news and updates on lung cancer from the ESMO Congress 2024.
Find the latest updates on lung cancer treatment and research from the IASLC 2024 World Conference on Lung Cancer.
Find the latest updates on lung cancer treatment and research from the 2024 ASCO Annual Meeting.
Our editors detail the latest data and innovations in the lung cancer space presented at ATS 2024.
Our editors provide coverage on the development of innovative cancer therapeutics, as presented at ESMO TAT 2024.
Our editors deliver in-depth coverage of NACLC 2023, a premier event offering the latest data on lung cancer advancements.
Our editors provide comprehensive coverage of ESMO Congress 2023, with a focus on lung cancer.
Our editors detail the latest data and innovations in the lung cancer space, as presented at WCLC 2023.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.